BioCentury
ARTICLE | Management Tracks

Woodman to guide Eisai’s cancer unit; plus Mengyu Lu joins Kirkland & Ellis in Hong Kong, and Splice Bio, Tarsus, Verastem, Fulcrum and more    

January 22, 2021 12:03 AM UTC

Richard Woodman joined Eisai Inc., the U.S. pharma unit of Eisai Co. Ltd. (Tokyo:4523), as chief clinical officer of its oncology business group. Before joining Eisai, Woodman was CMO and head of R&D of Onconova Therapeutics Inc. (NASDAQ:ONTX) and prior to that he spent 12 years at Novartis AG (NYSE:NVS; SIX:NOVN), where he was head of U.S. oncology clinical development and medical affairs.

Kirkland & Ellis added Mengyu Lu as a partner in the Capital Markets Practice Group of the firm’s Hong Kong office. Lu specializes in healthcare IPOs and other listings on the Stock Exchange of Hong Kong, M&A and compliance. She joins Kirkland from Sidley Austin, where she was a partner in the Hong Kong office. ...